Financial
FY2025 revenue $20.07bn (+19.9%); operating margin 18.0%; net income $2.90bn.
Balance sheet figures not captured from release.
Boston Scientific
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: BSX
FY2025 revenue $20.07bn (+19.9%); operating margin 18.0%; net income $2.90bn.
Balance sheet figures not captured from release.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$20.1bn | +19.9% | US$3.6bn | US$2.9bn | Boston Scientific |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Aug–Sep 2026: a cyberattack forced Boston Scientific to shut plants and distribution centres globally; the company said it would likely miss its Q3 and full-year 2026 sales and earnings guidance, after two earlier guidance cuts that year.
Cyber & information governance
Aug 2026: Boston Scientific disclosed to the SEC a cyberattack (detected 25 Aug) that disrupted order processing, manufacturing and shipping worldwide; it reported full restoration in Sep and said it found no evidence of compromise to its products. NHS DSPT status not yet checked.
Regulatory & clinical safety
2026: FDA classed two Boston Scientific recalls as most serious: AXIOS stent delivery systems (Feb 2026; 167 serious injuries, 3 deaths reported) and unused Infinion CX spinal cord stimulator leads (Jun 2026 letter; 1,081 serious injuries, no deaths).
Contract performance
Aug–Sep 2026: the cyberattack interrupted supply to hospitals; the CEO said many areas lacked adequate supply, some procedures were lost and some hospitals likely ordered from other suppliers before full restoration.
Competitors
No competitors linked yet.